BioLineRx (BLRX) Operating Expenses (2011 - 2025)

BioLineRx's Operating Expenses history runs 14 years deep, the most recent figure standing at -$3.5 million for Q4 2025.

• On a quarterly basis, Operating Expenses rose 6.37% year-over-year to -$3.5 million in Q4 2025; TTM through Dec 2025 was -$11.2 million, a 27.36% increase from a year earlier, with the FY2025 full-year figure at -$11.2 million, up 27.36% from the prior year.
• Operating Expenses fell to -$3.5 million in Q4 2025 per BLRX's latest filing, from -$2.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $4.3 million in Q2 2022 and bottomed at -$6.3 million in Q4 2021.
• The 5-year median for Operating Expenses is -$4.1 million (2023), against an average of -$3.5 million.
• Across the five-year window, Operating Expenses tumbled 199.19% in 2023 and soared 35.52% in 2025, its largest moves.
• Year by year, Operating Expenses stood at -$6.3 million in 2021, then climbed by 20.2% to -$5.0 million in 2022, then slipped by 5.19% to -$5.3 million in 2023, then increased by 28.79% to -$3.8 million in 2024, then climbed by 6.37% to -$3.5 million in 2025.
• Per Business Quant, the three latest BLRX Operating Expenses figures stand at -$3.5 million (Q4 2025), -$2.6 million (Q3 2025), and -$2.5 million (Q2 2025).